Estados Unidos · Plataformas y datos · MarketBeat

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Publicado por MarketBeat · Estados Unidos hace 1 h

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

También te puede interesar

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

Memory Stocks Are Plummetting. Jensen Huang Says the Bears Have It Wrong.

US accuses government contractor of leaking classified info to girlfriend’s Substack

Hooters closes 35-year-old location after shutting 55 restaurants

SpaceX’s 80,000 Cell Site Push A Win For AST SpaceMobile, Ericsson, Nokia, NextNav, Among Others, Says Roth Capital

Tryg (CPSE:TRYG) Stock Looks Below Fair Value On Capital Returns

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Compartir

También te puede interesar

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

Memory Stocks Are Plummetting. Jensen Huang Says the Bears Have It Wrong.

US accuses government contractor of leaking classified info to girlfriend’s Substack

Hooters closes 35-year-old location after shutting 55 restaurants

SpaceX’s 80,000 Cell Site Push A Win For AST SpaceMobile, Ericsson, Nokia, NextNav, Among Others, Says Roth Capital

Tryg (CPSE:TRYG) Stock Looks Below Fair Value On Capital Returns